

Maureen D Mayes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/33629/publications.pdf>

Version: 2024-02-01

154
papers

19,091
citations

20817

60
h-index

11607

135
g-index

158
all docs

158
docs citations

158
times ranked

14408
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. <i>Arthritis and Rheumatism</i> , 2008, 58, 15-25.	6.7	1,918
3	Cyclophosphamide versus Placebo in Scleroderma Lung Disease. <i>New England Journal of Medicine</i> , 2006, 354, 2655-2666.	27.0	1,421
4	Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019, 380, 2518-2528.	27.0	1,025
5	Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. <i>Arthritis and Rheumatism</i> , 2003, 48, 2246-2255.	6.7	809
6	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	10.7	754
7	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018, 378, 35-47.	27.0	417
8	Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1026-1034.	5.6	411
9	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 32-38.	0.9	394
10	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	21.4	351
11	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.7	321
12	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 1194-1203.	6.7	312
13	Scleroderma epidemiology. <i>Rheumatic Disease Clinics of North America</i> , 2003, 29, 239-254.	1.9	264
14	Epidemiology of systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 165-170.	4.3	257
15	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 2445-2454.	6.7	252
16	Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. <i>Arthritis and Rheumatism</i> , 2001, 44, 1359-1362.	6.7	243
17	High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. <i>Blood</i> , 2007, 110, 1388-1396.	1.4	240
18	Recombinant Human Relaxin in the Treatment of Scleroderma. <i>Annals of Internal Medicine</i> , 2000, 132, 871.	3.9	220

#	ARTICLE	IF	CITATIONS
19	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	3.5	201
20	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
21	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. <i>Arthritis and Rheumatism</i> , 1998, 41, 670-677.	6.7	175
22	Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 822-827.	0.9	172
23	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014, 48-49, 60-65.	6.5	170
24	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163
25	Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors. <i>Arthritis and Rheumatism</i> , 2007, 57, 318-326.	6.7	161
26	Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. <i>Arthritis and Rheumatism</i> , 2006, 54, 1961-1973.	6.7	156
27	Racial differences in scleroderma among women in Michigan. <i>Arthritis and Rheumatism</i> , 1997, 40, 734-742.	6.7	155
28	Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study. <i>PLoS Medicine</i> , 2016, 13, e1001976.	8.4	150
29	Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. <i>Arthritis Research and Therapy</i> , 2010, 12, R166.	3.5	148
30	A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 3540-3546.	6.7	125
31	Endothelin and endothelin receptor antagonists in systemic rheumatic disease. <i>Arthritis and Rheumatism</i> , 2003, 48, 1190-1199.	6.7	124
32	Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. <i>Journal of Autoimmunity</i> , 2010, 34, 155-162.	6.5	123
33	Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2015, 67, 3016-3026.	5.6	123
34	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 96-106.	10.7	118
35	Association of <i>TNFSF4 (OX40L)</i> polymorphisms with susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 550-555.	0.9	115
36	Risk of malignancy in scleroderma: A population-based cohort study. <i>Arthritis and Rheumatism</i> , 2005, 52, 2415-2424.	6.7	113

#	ARTICLE	IF	CITATIONS
37	HLAâ€“DPB1 and DPB2 are genetic loci for systemic sclerosis: A genomeâ€“wide association study in Koreans with replication in North Americans. <i>Arthritis and Rheumatism</i> , 2009, 60, 3807-3814.	6.7	109
38	Clinical and genetic factors predictive of mortality in early systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1403-1411.	6.7	106
39	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013, 3, e003563.	1.9	104
40	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. <i>Human Molecular Genetics</i> , 2013, 22, 4021-4029.	2.9	104
41	Primary Biliary Cirrhosis (PBC), PBC Autoantibodies, and Hepatic Parameter Abnormalities in a Large Population of Systemic Sclerosis Patients. <i>Journal of Rheumatology</i> , 2009, 36, 2250-2256.	2.0	101
42	Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. <i>Arthritis and Rheumatism</i> , 2006, 54, 3661-3669.	6.7	100
43	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	12.8	100
44	Association of thePTPN22 R620W polymorphism with antiâ€“topoisomerase lâ€“ and anticentromere antibodyâ€“positive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3945-3953.	6.7	99
45	Polymorphisms in <i>TBX21</i> and <i>STAT4</i> increase the risk of systemic sclerosis: Evidence of possible geneâ€“gene interaction and alterations in Th1/Th2 cytokines. <i>Arthritis and Rheumatism</i> , 2009, 60, 3794-3806.	6.7	98
46	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. <i>Human Molecular Genetics</i> , 2012, 21, 2825-2835.	2.9	98
47	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 379-386.	0.9	97
48	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2372-2380.	6.7	96
49	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 653-661.	6.7	96
50	Familial aggregation of primary Raynaud's disease. <i>Arthritis and Rheumatism</i> , 1996, 39, 1189-1191.	6.7	93
51	Approaches for identifying and defining environmentally associated rheumatic disorders. <i>Arthritis and Rheumatism</i> , 2000, 43, 243.	6.7	82
52	Genome-wide meta-analysis reveals shared new <i>loci</i> in systemic seropositive rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 311-319.	0.9	81
53	Clinical and serological features of systemic sclerosis in a multicenter African American cohort. <i>Medicine (United States)</i> , 2017, 96, e8980.	1.0	78
54	Disease and symptom burden in systemic sclerosis: a patient perspective. <i>Journal of Rheumatology</i> , 2007, 34, 1718-26.	2.0	77

#	ARTICLE	IF	CITATIONS
55	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. <i>Human Molecular Genetics</i> , 2012, 21, 926-933.	2.9	74
56	Meta-analysis of ImmunoChip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. <i>Genome Medicine</i> , 2018, 10, 97.	8.2	73
57	<i>IRF5</i> polymorphism predicts prognosis in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1197-1202.	0.9	72
58	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 55-62.	3.4	69
59	Increased β -Adrenergic responsiveness in idiopathic raynaud's disease. <i>Arthritis and Rheumatism</i> , 1989, 32, 61-65.	6.7	68
60	Morphea in Adults and Children Cohort III. <i>JAMA Dermatology</i> , 2013, 149, 1159.	4.1	68
61	Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. <i>Human Molecular Genetics</i> , 2019, 28, 3498-3513.	2.9	65
62	Novel identification of the <i>IRF7</i> region as an anticentromere autoantibody propensity locus in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 114-119.	0.9	62
63	CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. <i>Arthritis and Rheumatology</i> , 2017, 69, 1871-1878.	5.6	61
64	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	3.4	60
65	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2016, 18, 305.	3.5	58
66	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 602-607.	0.9	56
67	KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2018, 45, 1153-1158.	2.0	56
68	Clinical and serological features of systemic sclerosis in a Chinese cohort. <i>Clinical Rheumatology</i> , 2013, 32, 617-621.	2.2	55
69	Association of Interleukin 23 Receptor Polymorphisms with Anti-Topoisomerase-I Positivity and Pulmonary Hypertension in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 2715-2723.	2.0	54
70	Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. <i>Journal of Autoimmunity</i> , 2010, 35, 52-57.	6.5	54
71	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	1.9	53
72	New insight on the Xq28 association with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2032-2038.	0.9	52

#	ARTICLE	IF	CITATIONS
73	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	1.9	51
74	Cold-induced potentiation of β_2 -adrenergic vasoconstriction in primary raynaud's disease. <i>Arthritis and Rheumatism</i> , 1993, 36, 685-690.	6.7	48
75	SCLERODERMA EPIDEMIOLOGY. <i>Rheumatic Disease Clinics of North America</i> , 1996, 22, 751-764.	1.9	48
76	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2338-2344.	5.6	46
77	Anti-Fibrillar Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis. <i>Journal of Rheumatology</i> , 2011, 38, 1622-1630.	2.0	45
78	Genetics of scleroderma: implications for personalized medicine?. <i>BMC Medicine</i> , 2013, 11, 9.	5.5	43
79	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1371-1378.	0.9	43
80	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1521-1526.	0.9	41
81	Skin Gene Expression Correlates of Severity of Interstitial Lung Disease in Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2917-2927.	6.7	39
82	Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis. <i>Human Molecular Genetics</i> , 2010, 19, 707-719.	2.9	37
83	Genetics of systemic sclerosis. <i>Seminars in Immunopathology</i> , 2015, 37, 443-451.	6.1	37
84	Independent Replication and Metaanalysis of Association Studies Establish <i>TNFSF4</i> as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 997-1003.	2.0	35
85	Association of HLA-DPB1 with Scleroderma and Its Clinical Features in Chinese Population. <i>PLoS ONE</i> , 2014, 9, e87363.	2.5	35
86	Genetic factors in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007, 9, S5.	3.5	33
87	Determinants of Work Disability in Patients with Systemic Sclerosis: A Longitudinal Study of the GENISOS Cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 38-47.	3.4	33
88	Clinical, immunologic, and genetic features of familial systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2031-2037.	6.7	32
89	Minocycline is not effective in systemic sclerosis: Results of an open-label multicenter trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 553-557.	6.7	30
90	Separate influences of birth order and gravidity/parity on the development of systemic sclerosis. <i>Arthritis Care and Research</i> , 2010, 62, 418-424.	3.4	30

#	ARTICLE	IF	CITATIONS
91	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1233-1238.	0.9	30
92	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. <i>Arthritis Care and Research</i> , 2010, 62, 1772-1778.	3.4	29
93	Gender and ethnicity differences in patients with diffuse systemic sclerosis—analysis from three large randomized clinical trials. <i>Rheumatology</i> , 2011, 50, 335-342.	1.9	29
94	Association of the HLA-DRB1 with Scleroderma in Chinese Population. <i>PLoS ONE</i> , 2014, 9, e106939.	2.5	29
95	Identification of <i>IL12RB1</i> as a Novel Systemic Sclerosis Susceptibility Locus. <i>Arthritis and Rheumatology</i> , 2014, 66, 3521-3523.	5.6	29
96	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. <i>Autoimmunity</i> , 2015, 48, 542-551.	2.6	29
97	Machine learning predicts stem cell transplant response in severe scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1608-1615.	0.9	29
98	The genetics of scleroderma. <i>Current Opinion in Rheumatology</i> , 2012, 24, 677-684.	4.3	28
99	Genetics, Epigenetics, and Genomics of Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 345-366.	1.9	28
100	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S23-9.	0.8	28
101	Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016, 43, 1816-1824.	2.0	26
102	Antifibrillar Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 799-805.	2.0	25
103	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. <i>PLoS ONE</i> , 2018, 13, e0189498.	2.5	25
104	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosisâ€™Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 671-676.	5.6	24
105	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1040-1047.	0.9	24
106	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S131-5.	0.8	24
107	Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	23
108	Association Study of <i>ITGAM, ITGAX,</i> and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. <i>Journal of Rheumatology</i> , 2011, 38, 1033-1038.	2.0	22

#	ARTICLE	IF	CITATIONS
109	Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis. <i>American Journal of Medicine</i> , 2005, 118, 907-911.	1.5	21
110	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 1369-1379.	1.9	21
111	Nintedanib in Patients With Systemic Sclerosis-associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. <i>Arthritis and Rheumatology</i> , 2022, 74, 518-526.	5.6	21
112	Lack of Association of the CD247 SNP rs2056626 with Systemic Sclerosis in Han Chinese. <i>Open Rheumatology Journal</i> , 2014, 8, 43-45.	0.2	21
113	Genomic Risk Score impact on susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 118-127.	0.9	20
114	Systemic Sclerosis. , 2008, , 343-362.		20
115	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	3.5	18
116	A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease. <i>Scientific Reports</i> , 2020, 10, 1862.	3.3	18
117	What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?. <i>Current Opinion in Rheumatology</i> , 2013, 25, 686-691.	4.3	17
118	Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis. <i>Journal of Rheumatology</i> , 2020, 47, 1668-1677.	2.0	16
119	Brief Report: HLA-DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2772-2777.	5.6	15
120	Longitudinal patterns of pain in patients with diffuse and limited systemic sclerosis: integrating medical, psychological, and social characteristics. <i>Quality of Life Research</i> , 2017, 26, 85-94.	3.1	15
121	Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?. <i>Arthritis Research and Therapy</i> , 2021, 23, 259.	3.5	13
122	Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis. <i>Immunologic Research</i> , 2016, 64, 483-488.	2.9	12
123	The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. <i>ACR Open Rheumatology</i> , 2022, 4, 345-351.	2.1	12
124	Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221352.	0.9	12
125	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. <i>Arthritis and Rheumatology</i> , 2018, 70, 1654-1660.	5.6	10
126	Update on Systemic Sclerosis. <i>Current Allergy and Asthma Reports</i> , 2015, 15, 25.	5.3	9

#	ARTICLE	IF	CITATIONS
127	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1337-1338.	5.6	9
128	Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1399-1408.	5.6	9
129	Measuring Illness Behavior in Patients With Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2013, 65, 585-593.	3.4	8
130	Associations of Multiple <i>NOTCH4</i> Exonic Variants with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 184-189.	2.0	8
131	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. <i>Rheumatology</i> , 2022, 61, 4155-4162.	1.9	8
132	47XXY and 47XXX in Scleroderma and Myositis. <i>ACR Open Rheumatology</i> , 2022, 4, 528-533.	2.1	8
133	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16799.	1.0	7
134	Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	7
135	Predictors of Hand Contracture in Early Systemic Sclerosis and the Effect on Function: A Prospective Study of the GENISOS Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 1597-1604.	2.0	6
136	Blood Neutrophil Count and Neutrophil-Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis Cohorts. <i>Arthritis Care and Research</i> , 2023, 75, 648-656.	3.4	6
137	False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: A case series from a scleroderma referral center. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 56, 152052.	3.4	5
138	Epidemiology and Environmental Risk Factors. , 2012, , 17-28.		4
139	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	3.4	4
140	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	1.6	4
141	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017, 20, 99-106.	4.3	3
142	Characterization of the HLA-DR ¹ 21 third hypervariable region amino acid sequence according to charge and parental inheritance in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 46.	3.5	3
143	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. <i>Arthritis Care and Research</i> , 2021, , .	3.4	3
144	Epidemiology, Environmental, and Infectious Risk Factors. , 2017, , 11-24.		3

#	ARTICLE	IF	CITATIONS
145	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and Feasibility Studies, 2022, 8, 45.	1.2	3
146	Exome-Wide Association Analysis Suggests LRP2BP as a Susceptibility Gene for Endothelial Injury in Systemic Sclerosis in the Han Chinese Population. Journal of Investigative Dermatology, 2021, 141, 1254-1263.e6.	0.7	2
147	Predictors of Perceived Functional Status in Early Systemic Sclerosis: A Prospective Longitudinal Study of an Early Disease Cohort. Arthritis Care and Research, 2023, 75, 1066-1070.	3.4	2
148	Insights into the genetic basis of systemic sclerosis: immunity in human disease and in mouse models. Advances in Genomics and Genetics, 2014, , 143.	0.8	1
149	Stem cell transplantation for systemic sclerosis. The Cochrane Library, 0, , .	2.8	1
150	Systemic Sclerosis. Rheumatic Disease Clinics of North America, 2015, 41, xv-xvi.	1.9	1
151	Total Percutaneous Revascularization of the Hand to Treat Refractory Digital Ischemia in Advanced Systemic Sclerosis. JACC: Case Reports, 2022, 4, 161-166.	0.6	1
152	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2019, , .	1.9	0
153	OP0190â€¦META-ANALYSIS OF IMMUNOCHIP DATA OF FOUR AUTOIMMUNE DISEASES REVEALS NOVEL SINGLE-DISEASE AND CROSS-PHENOTYPE ASSOCIATIONS. , 2019, , .		0
154	Genetic Associations of Nonâ€œMajor Histocompatibility Complex Susceptibility Loci with Systemic Sclerosis in a Han Chinese Population. Journal of Investigative Dermatology, 2022, 142, 2039-2042.e7.	0.7	0